NASD · Healthcare · Biotechnology · Denmark
Ascendis Pharma A/S is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Ascendis Pharma A/S stock.
Overvalued: intrinsic value $75.44 per share, market price $229.95, margin of safety -204.8% (as of 2026-10-19).
A 4.2x revenue multiple, discounted for its losses, values the shares at $75.44; the price of $229.95 is 205% above that value.
Leak Score: 42/100 on 10 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
73 more in this industry show a wider margin of safety.
ASND is overvalued (as of the 2026-10-19 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $75.44; the price of $229.95 is 205% above that value.
$75.44 per share (as of the 2026-10-19 close), against a market price of $229.95. That is a margin of safety of -204.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
42 out of 100, which we rate "On Watch", on 10 of 12 value investing signals.